Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis’ discount for Afinitor in breast cancer has failed to convince NICE that the drug is cost-effective.

Advertisement

Related Content

NICE Rejects Novartis’ Afinitor, Citing Irrelevant Evidence And High Cost
Europe Transparency Initiatives May Aid Progress Toward Adaptive Licensing Systems
EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor
Regional Disparities Threaten Effectiveness Of U.K. Cancer Drugs Fund

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel